Overview


According to FutureWise analysis the market for immunoglobulin a (iga) nephropathy is expected to reach US$ 0.54 billion by 2031 at a CAGR of 20.32%.

The immunoglobulin A (IgA) nephropathy market expansion is powered by an increase in the number of R D activities. Increasing drug approvals and launches will also help to accelerate the market's growth rate. This will help the immunoglobulin A (IgA) nephropathy market expand. Furthermore, the market's expansion is fueled by investments in advanced technology development and the expansion of emerging markets. These factors will contribute to the expansion of the immunoglobulin A (IgA) nephropathy market. IgA nephropathy is a kidney disease in which IgA, a protein that aids the body's defence against external invaders, accumulates in the kidneys and damages them. This reduces their ability to screen. As a result, the kidneys begin to leak substances such as blood and protein into the urine. As a result, treatment options concentrate on reducing immune and inflammatory processes in the glomerulus and tubulointerstitium. As a result, many modern therapeutic techniques for chronic glomerular illnesses, such as renin-angiotensin blockade, proteinuria reduction, and blood pressure control, are appropriate.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Immunoglobulin A (IgA) Nephropathy Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Immunoglobulin A (IgA) Nephropathy Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AstraZeneca
  • Johnson and Johnson Private Limited
  • Cipla Inc.
  • Siemens Healthcare GmbH
  • Zydus Cadila
  • Hikma Pharmaceuticals PLC
  • LEO Pharma A/S
  • Fresenius Kabi AG
  • Accord Healthcare
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Alembic Pharmaceuticals Limited
  • Apotex Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Diagnosis

  • Iothalamate Clearance Test
  • Kidney Biopsy
  • Blood Tests
  • Urine Tests

By Disease Type

  • Primary IgA Nephropathy
  • Secondary IgA Nephropathy

By Symptoms

  • Hematuria
  • Proteinuria
  • Edema
  • Others

By Population Type

  • Pediatrics
  • Adults

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Treatment

  • Medication
  • Statin therapy
  • Omega-3 fatty acids
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin receptor blockers (ARBs)
  • Diuretics
  • Immunosuppressants
  • Kidney Transplantation
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Immunoglobulin A (IgA) Nephropathy Market By Diagnosis, By Disease Type, By Symptoms, By Population Type, By Route of Administration, By Treatment, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Immunoglobulin A (IgA) Nephropathy Market Variables, Trends and Scope
    •          1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Immunoglobulin A (IgA) Nephropathy Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Immunoglobulin A (IgA) Nephropathy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Immunoglobulin A (IgA) Nephropathy Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Iothalamate Clearance Test
        2. Kidney Biopsy
        3. Blood Tests
        4. Urine Tests

  • 8.   Immunoglobulin A (IgA) Nephropathy Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Primary IgA Nephropathy
        2. Secondary IgA Nephropathy

  • 9.   Immunoglobulin A (IgA) Nephropathy Market, By Symptoms Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hematuria
        2. Proteinuria
        3. Edema
        4. Others

  • 10.   Immunoglobulin A (IgA) Nephropathy Market, By Population Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pediatrics
        2. Adults

  • 11.   Immunoglobulin A (IgA) Nephropathy Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral
        3. Others

  • 12.   Immunoglobulin A (IgA) Nephropathy Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Medication
        2. Statin therapy
        3. Omega-3 fatty acids
        4. Angiotensin-converting enzyme (ACE) inhibitors
        5. Angiotensin receptor blockers (ARBs)
        6. Diuretics
        7. Immunosuppressants
        8. Kidney Transplantation
        9. Others

  • 13.   Immunoglobulin A (IgA) Nephropathy Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 14.   Immunoglobulin A (IgA) Nephropathy Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 15.   North America Immunoglobulin A (IgA) Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 16.   Latin America Immunoglobulin A (IgA) Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 17.   Europe Immunoglobulin A (IgA) Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 18.   Asia Pacific Immunoglobulin A (IgA) Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 19.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 20.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 21.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Johnson & Johnson Private Limited
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cipla Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Siemens Healthcare GmbH
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Zydus Cadila
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Hikma Pharmaceuticals PLC
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. LEO Pharma A/S
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Fresenius Kabi AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Accord Healthcare
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Abbott
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. F. Hoffmann-La Roche Ltd.
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
            11.4. Financial Overview
          11.5. Strategic Overview
         12. Mylan N.V.
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
        13. Teva Pharmaceutical Industries Ltd.
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Sanofi
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Novartis AG
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
        16. Sun Pharmaceutical Industries Ltd.
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Aurobindo Pharma
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. Lupin
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. Alembic Pharmaceuticals Limited
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
        20. Apotex Inc.
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview

  • 22.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 23.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients